US equities |
SPCX $175.12 ▲+2.35% NVDA $242.30 ▲+1.42% MU $1,070.25 ▲+0.59% AMD $653.80 ▲+3.49% MRVL $290.28 ▲+7.02% SNDK $1,680.00 ▼-1.42% AVGO $377.60 ▲+4.16% TSLA $380.99 ▲+0.60%
FinancialContent

Aytu BioPharma, Inc. - Common Stock (NQ:AYTU)

2.020 -0.020 (-0.98%)
Delayed Quote Updated: 10:39 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Aytu BioPharma Inc. (NASDAQ:AYTU) Shares Jump 125% on Q4 Beat and Strong EXXUA Launch ↗
Via Chartmill
News headline image
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million EXXUA net revenue of $6.6... 
From Aytu BioPharma, Inc.
Via ACCESS Newswire
News headline image
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
From Aytu BioPharma, Inc.
Via ACCESS Newswire
News headline image
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
Via ACCESS Newswire
Aytu BioPharma (NASDAQ:AYTU) Surges 23% as EXXUA Launch Gains Early Traction in Mixed Q3 Results ↗
Via Chartmill
Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costs ↗
Via Chartmill
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Via ACCESS Newswire
News headline image
Aytu (AYTU) Q3 2026 Earnings Transcript ↗
Aytu (AYTU) Q3 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
Via ACCESS Newswire
News headline image
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
Via ACCESS Newswire
News headline image
Aytu BioPharma AYTU Q2 2026 Earnings Transcript ↗
Aytu BioPharma AYTU Q2 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Via ACCESS Newswire
News headline image
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
Via ACCESS Newswire
News headline image
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
Via ACCESS Newswire
News headline image
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Via ACCESS Newswire
News headline image
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
Via ACCESS Newswire
News headline image
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
Via ACCESS Newswire
News headline image
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
Via ACCESS Newswire
News headline image
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Via ACCESS Newswire
News headline image
Aytu BioPharma Inc (NASDAQ:AYTU) Reports Q1 2026 Revenue Beat and Progress on EXXUA Launch ↗
Aytu BioPharma posts Q1 revenue beat and narrows loss, fueling investor optimism for its upcoming EXXUA depression drug launch. 
Via Chartmill
News headline image
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Via ACCESS Newswire
News headline image
Insights into Aytu BioPharma's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
Via ACCESS Newswire
News headline image
Aytu BioPharma to Present at Upcoming October 2025 Conferences
Via ACCESS Newswire
News headline image
11 Company Presentations Today at The MicroCap Rodeo Conference
Via ACCESS Newswire
News headline image
Aytu BioPharma to Present at Upcoming September 2025 Conferences
Via ACCESS Newswire
News headline image
Top movers in Wednesday's session ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >